New analysis of Phase II data at AACR assesses ImaginAb’s investigational CD8 ImmunoPET technology’s ability to predict response in immunotherapy

LOS ANGELES, April 14, 2023 /PRNewswire/ — ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPETâ„¢) imaging agent and radiopharmaceutical therapies (RPT) announces a poster presentation at AACR 2023 (# 3577 / 2 Poster PET, MRI, and CT Imaging…